BRIEF-U.S. FDA Approves Second Indication For Skyrizi(Risankizumab-Rzaa) To Treat Adults With Active Psoriatic Arthritis

BY Reuters
— 5:04 PM ET 01/21/2022

Jan 21 (Reuters) - Abbvie Inc (ABBV):

* U.S. FDA APPROVES SECOND INDICATION FOR SKYRIZI® (RISANKIZUMAB-RZAA) TO TREAT ADULTS WITH ACTIVE PSORIATIC ARTHRITIS

* ABBVIE (ABBV) - SKYRIZI MET PRIMARY ENDPOINT OF ACR20 AT WEEK 24 IN TWO PIVOTAL STUDIES, DEMONSTRATING SIGNIFICANT IMPROVEMENT IN JOINT SYMPTOMS Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Stock Details

Enter Company or Symbol. Press down arrow for suggestions, or Escape to return to entry field.

RELATED RESOURCES

BRIEF-U.S. FDA Approves Second Indication For Skyrizi(Risankizumab-Rzaa) To Treat Adults With Active Psoriatic Arthritis

More ABBV News